INSA Chooses AAGP™ to Present at Annual GECO Conference

PROTOKINETIX INC.            (PKTX: OTCBB)
Vancouver, British Columbia, July 21, 2006

Dr. John Todd, President and CEO of ProtoKinetix, Inc., is pleased to announce today that INSA (France’s National Institute of Applied Sciences) has chosen ProtoKinetix’ AAGP™ to feature at the annual GECO (Groupe d'Etudes de Chimie Organique) conference. GECO is a major French congress which gathers Senior researchers, Universities and Pharmaceutical / Chemical corporations once a year for a study group of organic chemistry. This academic and industrial forum is a series of presentations of recent projects that initiate discussions, collaboration opportunities, and communication with laboratories and companies.

INSA’s presentation will be made by Dr. Geraldine Deliencourt of the University of Rouen. Dr Deliencourt has been the lead researcher on behalf of INSA and ProtoKinetix since the original development of the family of AAGP™ molecules. Only molecules deemed to be of significant scientific importance are highlighted throughout this conference. The timing of these meetings will coincide with the introduction of PKTX to several major institutions across Europe.

About ProtoKinetix:

ProtoKinetix Inc. is a Biotechnical Company dedicated to the development of a family of synthetic antifreeze glycoproteins (AAGP™) for human and veterinary medicine, the biotechnology and cosmetic industries, and as a food additive. Using previously published research on native antifreeze proteins and antifreeze glycoproteins as a guide, and coordinating a vast pool of world recognized intellectual talent in a networked environment, PKTX is conducting rapid and meaningful research with a view to developing markets for this very useful family of molecules. Sign up for free automatic email news alerts at our new website at: www.protokinetix.com

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements.  Some information included in this press release contains statements that are forward-looking.  Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company.  For a description of additional risks and uncertainties, please refer to the Company’s filings with the Securities and Exchange Commission.

On behalf of the Board of Directors,

Dr. John Todd - President

Company Office:                       
Suite # 1500           
885 West Georgia Street           
Vancouver, BC  V6C 3E8           

Investor Contact:
BCGU, Business Consulting Group Unlimited
In the U.S.:  (888) 772-1288
Outside the U.S.: (760) 230.2300 ext 206